BamSEC and AlphaSense Join Forces
Learn More

Travere Therapeutics Inc. – Material Contracts

NASDAQ: TVTX    
Share price (9/29/26): $59.99    
Market cap (9/29/26): $5.655 billion
Search in Documents
Key Exhibits
External Links

Material Contracts Filter

EX-10.2
from 8-K 28 pages Employment Agreement
12/34/56
EX-10.1
from 8-K 11 pages September 21, 2026 Eric Dube, PH.D. via E-Mail Re: Transition and Separation Agreement Dear Eric: This Letter Agreement (The “Agreement”) Sets Forth Our Mutual Understanding Regarding Your Decision to Step Down as President and Chief Executive Officer of Travere Therapeutics, Inc., a Delaware Corporation (The “Company”)
12/34/56
EX-10.2
from 10-Q 76 pages Certain Confidential Information Contained in This Document, Marked by [*], Has Been Omitted Because It Is Both (I) Not Material and (II) Is the Type of Information That the Registrant Treats as Private or Confidential. Exclusive License and Collaboration Agreement by and Between Everest Medicines (Singapore) Pte. Ltd., Travere Therapeutics, Inc. and Solely for the Purpose of Section 16.15 (Parent Guarantee) Everest Medicines Limited Dated as of June 1, 2026
12/34/56
EX-10.1
from 10-Q 2 pages Non-Employee Director Compensation Program
12/34/56
EX-10.9
from 10-K 4 pages 2026 Travere Therapeutics, Inc. Executive Officer Annual Bonus Plan
12/34/56
EX-10.2
from 10-Q 5 pages Certain Confidential Information Contained in This Document, Marked by [***], Has Been Omitted Because It Is Both (I) Not Material and (II) Is the Type of Information That the Registrant Treats as Private or Confidential. Amendment No. 2 to License and Collaboration Agreement
12/34/56
EX-10.2
from 10-Q 2 pages Non-Employee Director Compensation Program
12/34/56
EX-10.9
from 10-K 4 pages 2025 Travere Therapeutics, Inc. Executive Officer Annual Bonus Plan
12/34/56
EX-10.1
from 10-Q 3 pages Certain Confidential Information Contained in This Document, Marked by [***], Has Been Omitted Because It Is Both (I) Not Material and (II) Is the Type of Information That the Registrant Treats as Private or Confidential. Amendment No. 5 to Sublicense Agreement
12/34/56
EX-10.1
from 10-Q 2 pages Non-Employee Director Compensation Program
12/34/56
EX-10.32
from 10-K 10 pages Certain Confidential Information Contained in This Document, Marked by [***], Has Been Omitted Because It Is Both (I) Not Material and (II) Is the Type of Information That the Registrant Treats as Private or Confidential. Fifth Amendment to Trademark License and Supply Agreement
12/34/56
EX-10.30
from 10-K 5 pages Certain Confidential Information Contained in This Document, Marked by [***], Has Been Omitted Because It Is Both (I) Not Material and (II) Is the Type of Information That the Registrant Treats as Private or Confidential
12/34/56
EX-10.29
from 10-K 3 pages Certain Confidential Information Contained in This Document, Marked by [***], Has Been Omitted Because It Is Both (I) Not Material and (II) Is the Type of Information That the Registrant Treats as Private or Confidential. Amendment One to the Third Amendment to Trademark License and Supply Agreement
12/34/56
EX-10.28
from 10-K 3 pages Third Amendment to Trademark License and Supply Agreement
12/34/56
EX-10.25
from 10-K 15 pages Certain Confidential Information Contained in This Document, Marked by [***], Has Been Omitted Because It Is Both (I) Not Material and (II) Is the Type of Information That the Registrant Treats as Private or Confidential. Trademark License & Supply Agreement
12/34/56
EX-10.10
from 10-K 4 pages 2024 Travere Therapeutics, Inc. Executive Officer Annual Bonus Plan
12/34/56
EX-10.8
from 10-K 2 pages Non-Employee Director Compensation Program
12/34/56
EX-10.2
from 10-Q 30 pages Certain Confidential Information Contained in This Document, Marked by [***], Has Been Omitted Because It Is Both (I) Not Material and (II) Is the Type of Information That the Registrant Treats as Private or Confidential. Asset Purchase Agreement
12/34/56
EX-10.1
from 8-K 85 pages Certain Confidential Information Contained in This Document, Marked by [*], Has Been Omitted Because It Is Both (I) Not Material and (II) Is the Type of Information That the Registrant Treats as Private or Confidential. Asset Purchase Agreement by and Between Travere Therapeutics, Inc. and Mirum Pharmaceuticals, Inc. Dated as of July 16, 2023
12/34/56
EX-10.2
from 10-Q 20 pages Employment Agreement
12/34/56